Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 735 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Biliary Diseases Clear all

Conditions: Liver Failure, Liver Diseases, Alcoholic, Liver Diseases, Pain, Postoperative, Transplant; Failure, Liver, Liver Cirrhosis, Biliary
Interventions: BRIDGE device; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Primary Biliary Cirrhosis
Interventions: NGM282, Placebo; Biological
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 7
States / cities: Phoenix, Arizona • Coronado, California • Detroit, Michigan + 4 more

Conditions: Biliary Atresia
Interventions: Not listed
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: Up to 6 Months
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2029
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma
Interventions: certepetide, Durvalumab, Cisplatin, Gemcitabine, FOLFOX regimen, Placebo; Drug
Lead sponsor: Lisata Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 19
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more

Conditions: Primary Biliary Cirrhosis
Interventions: Elafibranor 80mg, Placebo; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 46
States / cities: Chandler, Arizona • Los Angeles, California • Sacramento, California + 34 more

Conditions: Primary Sclerosing Cholangitis
Interventions: quality of life survey; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer, Nausea and Vomiting, Pancreatic Cancer, Primary Peritoneal Cavity Cancer, Small Intestine Cancer
Interventions: palonosetron hydrochloride, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 69
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Moline, Illinois + 37 more

Conditions: Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor, Liver Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions: fluorouracil, irinotecan hydrochloride, leucovorin calcium, pharmacogenomic studies, pharmacological study; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer, Prostate Cancer, Urothelial Carcinoma, Colorectal Cancer, Triple Negative Breast Cancer, High Grade Ovarian Serous Adenocarcinoma, Diffuse Large B Cell Lymphoma, Renal Cell Cancer Metastatic
Interventions: ZM008; Biological
Lead sponsor: Zumutor Biologics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • Austin, TX 78758, Texas • San Antonio, Texas

Conditions: Localized Malignant Solid Neoplasm, Anal Cancer, Bladder (Urothelial, Transitional Cell) Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastric Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Head and Neck Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Sarcoma
Interventions: Exercise Intervention, Telemedicine, Aerobic Exercise Intervention, Accelerometry, Questionnaire Administration, Interview, Electronic Health Record Review; Other · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 30
States / cities: Dublin, California • Fremont, California • Fresno, California + 23 more

Conditions: Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases
Interventions: Rosuvastatin; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cholangiocarcinoma
Interventions: Fimaporfin and Gemcitabine, Gemcitabine/Cisplatin chemotherapy; Drug
Lead sponsor: PCI Biotech AS; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Duarte, California • Atlanta, Georgia • Chicago, Illinois + 3 more

Conditions: Bile Duct Diseases
Interventions: Angled guidewire, Straight guidewire; Device
Lead sponsor: Neev Mehta; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Advanced Solid Tumors, HER2 Mutation
Interventions: BAY2927088; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 11
States / cities: Birmingham, Alabama • Duarte, California • Fort Myers, Florida + 8 more

Conditions: Advanced MTAP-null Solid Tumors
Interventions: Anvumetostat, Docetaxel, Comparator Anvumetostat Test Tablet; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 30
States / cities: Duarte, California • Glendale, California • Oxnard, California + 24 more

Conditions: Primary Sclerosing Cholangitis
Interventions: DUR-928; Drug
Lead sponsor: Durect; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: San Francisco, California • Jacksonville, Florida • Jackson, Mississippi + 1 more

Conditions: Primary Sclerosing Cholangitis (PSC)
Interventions: Genetic Analysis; Genetic
Lead sponsor: Mayo Clinic; Other
Eligibility: 5 Years to 90 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms, Colorectal Cancer, Cholangiocarcinoma, Bile Duct Neoplasms, Bile Duct Cancer, Adrenocortical Carcinoma (ACC), Adrenal Cortical Carcinoma, Adrenal Gland Cancer, Adrenal Gland Neoplasms, Adrenal Cortex Neoplasms
Interventions: Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP), Floxuridine; Drug · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, Cholangiocarcinoma, Liver Cancer
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 9,150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2050
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Primary Sclerosing Cholangitis (PSC)
Interventions: SpyGlass DS I - II; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Davis, California • Sacramento, California • Salt Lake City, Utah

Conditions: Cholelithiasis, Biliary Dyskinesia
Interventions: SILS, Standard Laparoscopic Cholecystectomy; Procedure
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 1 Year to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Cholestasis
Interventions: Linerixibat; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 11
States / cities: Davis, California • West Hollywood, California • Miami, Florida + 8 more

Conditions: Biliary Diseases, Pancreatic Duct Disorder
Interventions: Exalt Model D, Reusable; Device
Lead sponsor: Rush University Medical Center; Other
Eligibility: 19 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Gallbladder Carcinoma, Metastatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Cholangiocarcinoma
Interventions: Atezolizumab, Biopsy, Biospecimen Collection, Cobimetinib, Computed Tomography, Magnetic Resonance Imaging; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 41
States / cities: Duarte, California • Sacramento, California • South Pasadena, California + 31 more

Search by objective public record fields.

BRIDGE Device for Post-operative Pain Control

Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

A Prospective Database of Infants With Cholestasis

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

Quality of Life in Patients With Primary Sclerosing Cholangitis

Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer

Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Distance-Based Exercise to Preserve Function and Prevent Disability

Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study

PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer

Angled-tip vs. Straight-tip Guidewire in Biliary Cannulation

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)

Genomics of Primary Sclerosing Cholangitis (PSC)

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Biobank for Cholestatic Liver Diseases.

Cholangioscopy in Primary Sclerosing Cholangitis (PSC)

Single Incision Laparoscopic Surgery (SILS) Versus Laparoscopic Cholecystectomy

Linerixibat Long-term Safety, and Tolerability Study

Exalt Single-use Duodenoscope Vs Reusable Scope, a Randomized Controlled Trial

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer